These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

627 related articles for article (PubMed ID: 18729019)

  • 1. Antibody therapeutics, antibody engineering, and the merits of protein stability.
    Demarest SJ; Glaser SM
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):675-87. PubMed ID: 18729019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic bispecific antibodies: The selection of stable single-chain fragments to overcome engineering obstacles.
    Mabry R; Snavely M
    IDrugs; 2010 Aug; 13(8):543-9. PubMed ID: 20721825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering antibodies for stability and efficient folding.
    Honegger A
    Handb Exp Pharmacol; 2008; (181):47-68. PubMed ID: 18071941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability engineering of scFvs for the development of bispecific and multivalent antibodies.
    Miller BR; Demarest SJ; Lugovskoy A; Huang F; Wu X; Snyder WB; Croner LJ; Wang N; Amatucci A; Michaelson JS; Glaser SM
    Protein Eng Des Sel; 2010 Jul; 23(7):549-57. PubMed ID: 20457695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies.
    Davis JH; Aperlo C; Li Y; Kurosawa E; Lan Y; Lo KM; Huston JS
    Protein Eng Des Sel; 2010 Apr; 23(4):195-202. PubMed ID: 20299542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of aggregation prone regions of therapeutic proteins.
    Chennamsetty N; Voynov V; Kayser V; Helk B; Trout BL
    J Phys Chem B; 2010 May; 114(19):6614-24. PubMed ID: 20411962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secretion from bacterial versus mammalian cells yields a recombinant scFv with variable folding properties.
    Vendel MC; Favis M; Snyder WB; Huang F; Capili AD; Dong J; Glaser SM; Miller BR; Demarest SJ
    Arch Biochem Biophys; 2012 Oct; 526(2):188-93. PubMed ID: 22230329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural understanding of stabilization patterns in engineered bispecific Ig-like antibody molecules.
    Jordan JL; Arndt JW; Hanf K; Li G; Hall J; Demarest S; Huang F; Wu X; Miller B; Glaser S; Fernandez EJ; Wang D; Lugovskoy A
    Proteins; 2009 Dec; 77(4):832-41. PubMed ID: 19626705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein engineering of antibodies.
    Sandhu JS
    Crit Rev Biotechnol; 1992; 12(5-6):437-62. PubMed ID: 1423650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers.
    Meli G; Visintin M; Cannistraci I; Cattaneo A
    J Mol Biol; 2009 Apr; 387(3):584-606. PubMed ID: 19361429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering of stable bispecific antibodies targeting IL-17A and IL-23.
    Mabry R; Lewis KE; Moore M; McKernan PA; Bukowski TR; Bontadelli K; Brender T; Okada S; Lum K; West J; Kuijper JL; Ardourel D; Franke S; Lockwood L; Vu T; Frank A; Appleby MW; Wolf A; Reardon B; Hamacher NB; Stevens B; Lewis P; Lewis KB; Gilbertson DG; Lantry M; Julien SH; Ostrander C; Chan C; Byrnes-Blake K; Brody J; Presnell S; Meengs B; Levin SD; Snavely M
    Protein Eng Des Sel; 2010 Mar; 23(3):115-27. PubMed ID: 20022918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology.
    Huang C
    Curr Opin Biotechnol; 2009 Dec; 20(6):692-9. PubMed ID: 19889530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-domain antibodies as building blocks for novel therapeutics.
    Saerens D; Ghassabeh GH; Muyldermans S
    Curr Opin Pharmacol; 2008 Oct; 8(5):600-8. PubMed ID: 18691671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.
    Muda M; Gross AW; Dawson JP; He C; Kurosawa E; Schweickhardt R; Dugas M; Soloviev M; Bernhardt A; Fischer D; Wesolowski JS; Kelton C; Neuteboom B; Hock B
    Protein Eng Des Sel; 2011 May; 24(5):447-54. PubMed ID: 21498564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein-protein interaction regulates proteins' mechanical stability.
    Cao Y; Yoo T; Zhuang S; Li H
    J Mol Biol; 2008 May; 378(5):1132-41. PubMed ID: 18433770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineered antibodies take center stage.
    Huston JS; George AJ
    Hum Antibodies; 2001; 10(3-4):127-42. PubMed ID: 11847424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leveraging SBDD in protein therapeutic development: antibody engineering.
    Gilliland GL; Luo J; Vafa O; Almagro JC
    Methods Mol Biol; 2012; 841():321-49. PubMed ID: 22222459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody engineering and modification technologies.
    Filpula D
    Biomol Eng; 2007 Jun; 24(2):201-15. PubMed ID: 17466589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The assembly of single domain antibodies into bispecific decavalent molecules.
    Stone E; Hirama T; Tanha J; Tong-Sevinc H; Li S; MacKenzie CR; Zhang J
    J Immunol Methods; 2007 Jan; 318(1-2):88-94. PubMed ID: 17141798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design.
    Von Kreudenstein TS; Escobar-Carbrera E; Lario PI; D'Angelo I; Brault K; Kelly J; Durocher Y; Baardsnes J; Woods RJ; Xie MH; Girod PA; Suits MD; Boulanger MJ; Poon DK; Ng GY; Dixit SB
    MAbs; 2013; 5(5):646-54. PubMed ID: 23924797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.